The next FDA prescription drug user fee package for 2028–2032 is under White House review, according to sources familiar with the process. The reported examination centers on the deal reached by FDA and biopharma stakeholders that would set the user-fee amounts the industry pays to support agency capacity during the next multi-year cycle. The timing matters for companies planning submissions and manufacturing timelines that depend on predictable review resourcing. For the sector, the user-fee framework acts as a lever for review speed, staffing priorities, and programmatic enhancements across both small molecule and biologics pathways. As the White House weighs the agreement, biopharma stakeholders will likely focus on how the final terms could translate into operational targets for FDA in the 2028–2032 period.